Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘What’s Really Important Is, What Are We Doing Next?’: Sandoz On Biosimilar Ambitions

Adalimumab, Denosumab, Natalizumab, And Aflibercept All Under Discussion

Executive Summary

In the second part of Generics Bulletin’s exclusive interview with Sandoz’s global head for biosimilars, Peter Stenico, he discusses the company’s various near-term pipeline opportunities, as well as his expectations for LOE opportunities in the next decade.

You may also be interested in...



What’s Next? Five Things To Look Out For In December

Generics Bulletin previews the most noteworthy and anticipated events for December 2023.

Meitheal Looks To Chinese Parent To Bring In Three US Insulin Biosimilars

Designed as its US commercial arm following a major investment four years ago, Chinese player Nanjing King-Friend Biochemical Pharmaceutical has signed a deal allowing Meitheal Pharmaceuticals to sell three insulin biosimilars in the US.

Polpharma Biologics CEO Discusses Natalizumab Milestone

In the wake of a positive opinion from the EMA’s CHMP recommending granting a marketing authorization for the firm’s Sandoz-partnered natalizumab biosimilar, Polpharma Biologics CEO Michael Soldan talks to Generics Bulletin about the significance of the development.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel